4.7 Review

ATP-binding cassette (ABC) drug transporters in the developing blood-brain barrier: role in fetal brain protection

Journal

CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 79, Issue 8, Pages -

Publisher

SPRINGER BASEL AG
DOI: 10.1007/s00018-022-04432-w

Keywords

Blood-brain barrier; ABC transporter; Fetal; Prenatal glucocorticoids; Maternal infection

Funding

  1. Foundation grant from Canadian Institutes of Health Research [CIHR: FDN-148368]
  2. Queen Elizabeth II Graduate Scholarship in Science and Technology (QEIIGSST)
  3. Higher Education Personnel Improvement Coordination (Coordenacao de Aperfeicoamento Pessoal de Nivel Superior [CAPES]) [001, 88887.370196/2019-00]
  4. National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) [10578/2020-5]
  5. Research Support Foundation of Minas Gerais State (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais [FAPEMIG]) [APQ-00338-18]

Ask authors/readers for more resources

The blood-brain barrier plays an important role in protecting the developing brain from environmental toxins and xenobiotics. Drug transporters, such as P-gp and BCRP, are crucial for developmental homeostasis and fetal brain protection. Various factors can modulate the expression and function of these drug transporters, either increasing or inhibiting brain protection.
The blood-brain barrier (BBB) provides essential neuroprotection from environmental toxins and xenobiotics, through high expression of drug efflux transporters in endothelial cells of the cerebral capillaries. However, xenobiotic exposure, stress, and inflammatory stimuli have the potential to disrupt BBB permeability in fetal and post-natal life. Understanding the role and ability of the BBB in protecting the developing brain, particularly with respect to drug/toxin transport, is key to promoting long-term brain health. Drug transporters, particularly P-gp and BCRP are expressed in early gestation at the developing BBB and have a crucial role in developmental homeostasis and fetal brain protection. We have highlighted several factors that modulate drug transporters at the developing BBB, including synthetic glucocorticoid (sGC), cytokines, maternal infection, and growth factors. Some factors have the potential to increase expression and function of drug transporters and increase brain protection (e.g., sGC, transforming growth factor [TGF]-beta). However, others inhibit drug transporters expression and function at the BBB, increasing brain exposure to xenobiotics (e.g., tumor necrosis factor [TNF], interleukin [IL]-6), negatively impacting brain development. This has implications for pregnant women and neonates, who represent a vulnerable population and may be exposed to drugs and environmental toxins, many of which are P-gp and BCRP substrates. Thus, alterations in regulated transport across the developing BBB may induce long-term changes in brain health and compromise pregnancy outcome. Furthermore, a large portion of neonatal adverse drug reactions are attributed to agents that target or access the nervous system, such as stimulants (e.g., caffeine), anesthetics (e.g., midazolam), analgesics (e.g., morphine) and antiretrovirals (e.g., Zidovudine); thus, understanding brain protection is key for the development of strategies to protect the fetal and neonatal brain.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available